Novo Nordisk, Eli Lilly slide after Trump comments on weight loss drug pricing
Investing.com - KeyBanc has reiterated its Overweight rating and $220.00 price target on AptarGroup (NYSE:ATR) following the company’s investor day. The stock, currently trading at $137.05, sits near its 52-week low, with analyst targets ranging from $153 to $220.
The investor day, which took place after AptarGroup announced its 32nd consecutive dividend increase, primarily focused on the company’s pharmaceutical business, which KeyBanc noted adds 7-10% of revenue annually through its growing pipeline. According to InvestingPro data, the company has maintained dividend payments for 33 consecutive years, with a current dividend yield of 1.31%.
KeyBanc highlighted that the pharmaceutical segment has the most bullish targets within AptarGroup’s portfolio, with projected growth of 7-11% and adjusted EBITDA margins of 32-36%.
AptarGroup reiterated its long-term targets of 4-7% revenue growth and 21-23% adjusted EBITDA margins during the investor day, which KeyBanc indicated provides visibility into the company’s future performance.
KeyBanc observed that as the pharmaceutical business increases in mix and demonstrates growth similar to peers, there may be room for multiple expansion in AptarGroup’s stock.
In other recent news, AptarGroup Inc . reported its second-quarter 2025 financial results, surpassing earnings expectations with an adjusted earnings per share (EPS) of $1.66, compared to the forecasted $1.59. Revenue for the quarter also exceeded projections, reaching $966 million against the expected $952.15 million. Additionally, AptarGroup announced an increase in its quarterly cash dividend by nearly 7% to $0.48 per share, raising the annualized dividend to $1.92 per share. This marks the second consecutive year of significant dividend hikes for the company. The dividend will be paid on November 13, 2025, to shareholders of record as of October 23, 2025. The company stated that the dividend increase reflects confidence in its business outlook and sustained growth expectations, particularly in its pharmaceutical segment. Despite the positive earnings and revenue results, the company’s stock experienced a decline, which might be attributed to investor concerns over future challenges discussed during the earnings call.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.